Work

Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma

Year: 2019

Type: review

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2019.01.017

Authors: Matthew K. Labriola, Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, Tian Zhang

Institutions: Duke Cancer Institute, Duke University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Pfizer, Astellas Pharma US, AstraZeneca, Bayer, Merck, Novartis, Sanofi, Gilead Sciences, AbbVie, Bayer Corporation, Seattle Genetics, Exelixis, Clovis Oncology, National Institutes of Health, Genentech, National Institute of General Medical Sciences, Janssen Biotech

Awards: Medical Scientist Training Program, G7423759087, Medical Scientist Training Program Training Grant

OpenAlex ID: W2913500231

FWCI: 1.096

Cites: 89

Cited by: 41

Related to: 10